ACTSI Investigator Dr. Young-sup Yoon in the News
Young-Sup Yoon, MD, PhD, ACTSI investigator and associate professor in the Cardiology Division at Emory University. His lab is focused on generating stem cells ranging from adult stem cells to pluripotent stem cells, and investigating their therapeutic utility in various cardiovascular diseases such as myocardial infarction, heart failure, peripheral vascular ischemia, diabetic neuropathy, and lymphedema. They have strong mechanistic interest in angiogenesis, vasculogenesis, cardiomyogenesis, and lymphangiogenesis. They also have expanded their interests into reprogramming of somatic cells into endothelial cells and cardiomyocytes, and engineering stem cell-derived cardiac, and vascular cells with biomaterials. In his free time, Yoon loves music and reading books. He plays a guitar and enjoys listening to music and arranging and singing songs. He is also involved in worship and music ministries in a local church.
Emory Daily Pulse | Learn about our regenerative medicine program
May 17, 2016
Lab Land | CV cell therapy: bridge between nurse and building block
November 16, 2015
Lab Land | Cardiac cell therapy: three papers at a glance
September 24, 2014
Lab Land | Molecular beacons shine path to cardiac muscle repair
September 5, 2013
Emory News Center | Molecular beacons light path to cardiac muscle repair
September 4, 2013
Publications:
“Bone marrow-derived mesenchymal stem cells improve diabetic neuropathy by direct modulation of both angiogenesis and myelination in peripheral nerves.” Cell Transplant. 2016;25(2):313-26.
ACS Applied Materials & Interfaces, March 2, 2016
Therapeutic Effects of Late Outgrowth Endothelial Progenitor Cells or Mesenchymal Stem Cells Derived from Human Umbilical Cord Blood on Infarct Repair
International Journey of Cardiology, January 15, 2016
“Non-genetic purification of ventricular cardiomyocytes from differentiating embryonic stem cells through molecular beacons targeting IRX-4“ Stem Cell Reports. 2015 Dec 8;5(6):1239-49.
Diabetic Mesenchymal Stem Cells are Ineffective for Improving Limb Ischemia Due to their Impaired Angiogenic Capability
Cell Transplantation, 2015
Enhanced Therapeutic Neovascularization by CD31-Expressing Cells and Embryonic Stem Cell-Derived Endothelial Cells Engineered with Chitosan Hydrogel Containing VEGF-Releasing Microtubes
Biomaterials, September 2015
“Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair.” Sci Rep. 2015 Jun 12;5:11019.
Molecular Beacon-enabled Purification of Living Cells by Targeting Cell Type-specific mRNAs
Nature Protocols, October 2014
Cell Therapy with Embryonic Stem Cell-derived Cardiomyocytes Encapsulated in Injectable Nanomatrix Gel Enhances Cell Engraftment and Promotes Cardiac Repair
ACS Nano, October 28, 2014
Cultured Human Bone Marrow-derived CD31(+) Cells are Effective for Cardiac and Vascular Repair through Enhanced Angiogenic, Adhesion, and Anti-inflammatory Effects
Journal of the American College of Cardiology, October 21, 2014
“Evaluation of the effect of expansion and shear stress on a self-assembled endothelium mimicking nanomatrix coating for drug eluting stents in vitro and in vivo.” Biofabrication. 2014 Sep;6(3):035019.
The Modulation of Cardiac Progenitor Cell Function by Hydrogel-dependent Notch1 Activation
Biomaterials, September 2014
Effect of Progenitor Cell Mobilization With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Peripheral Artery Disease: A Randomized Clinical Trial.
The Journal of the American Medical Association, December 25, 2013
“Purification of Cardiomyocytes from Differentiating Pluripotent Stem Cells Using Molecular Beacons Targeting Cardiomyocyte-Specific mRNA.” Circulation. 2013 Aug 30.
Yoon received a $2.4 million NIH DP3 award for his project entitled, "Effects of Reprogrammed and Engineered MSCs on Diabetic Complications."
Yoon’s invention of a “Generation of Transgene-Free Induced Pluripotent Stem Cells from Somatic Cells by Small Molecule Chemicals” was honored on March 7, 2013 as Emory University’s Innovation of 2012 at the OTT Celebration of Technology and Innovation. Chemically-induced pluripotent stem cells was named the Innovation of 2012 at the 7th annual Celebration of Technology and Innovation in March 2012.Yoon received a new NIH R01 grant from the National Heart, Lung, and Blood Institute for his project entitled, “Stem cell-based therapy for lymphedema.”
Dr. Yoon was recently accepted as a member of the American Society for Clinical Investigation (ASCI) and will be inducted next month at the new member ceremony. The ASCI is an honor society of physician-scientists, those who translate findings in the laboratory to the advancement of clinical practice. Founded in 1908, the Society is home to more than 3,000 members who are in the upper ranks of academic medicine and industry.